By Kate Baggaley
A new survey from the healthcare services firm Vizient sheds light on the state of biosimilar adoption in the United States ahead of next year’s expected launch of numerous biosimilars for the immunosuppressive adalimumab (Humira, AbbVie).
The respondents included 124 pharmacy executives and professionals, 80% of whom said their institutions had implemented a systemwide review process for biosimilar adoption to their formularies. However, the results also indicated